New policy memo – Data TRANSPARENCY For Public Health

New article by Zhuoying Lin published in the Journal of Science Policy and Governance!

Policy Memo: The FDA Accelerated Approval Program: Data Transparency for Public Health

The article dives into a lack of transparency surrounding the FDA and its current accelerated approved drugs, which could lead to less safety for patients and consumers. The memo calls for greater transparency on the behalf of the FDA and calls for them to release the de-identified clinical trial data upon accelerated approval, which would allow both physicians and patients more educated and safer choices.